EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Treatment of a large cohort of childhood chronic non‐infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapy

Ilaria Maccora iD, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V Ramanan, Gabriele Simonini

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70090 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Ilaria Maccora und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Adalimumab, Methotrexate, Uveitis, Antirheumatic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in Juvenile Idiopathic Arthritis associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU.

Methods

Retrospective multicenter study involving the rheuma/ophthalmology units at Florence and Bristol. We included children with cCIU, who received at least one systemic treatment. Ocular inflammation and treatment response were assessed according to the standardized Uveitis Nomenclature (SUN).

Findings

116 cCIU received at least one systemic treatment (93 methotrexate, 22 adalimumab, 1 mycophenolate), while 60 of them received an additional second‐line (45 adalimumab, 14 mycophenolate and 1 tocilizumab). Children treated with adalimumab (+/‐methotrexate) as first‐line were more likely to achieve remission than methotrexate alone (χ 2 31.35 p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabMethotrexateUveitisAntirheumatic AgentsImmunosuppressive AgentsHumansChildFemaleMaleRetrospective StudiesChronic DiseaseChild, PreschoolTreatment OutcomeAdolescentRemission InductionMycophenolic AcidAntibodies, Monoclonal, HumanizedDrug Therapy, Combination

Substanzen

AdalimumabMethotrexateAntirheumatic AgentsImmunosuppressive AgentsMycophenolic AcidAntibodies, Monoclonal, Humanizedtocilizumab

Autor:innen und Institutionen

  • Pediatric Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • NeuroFARBA Department, University of Florence, Florence, Italy.
  • Bristol Eye Hospital, Bristol, United Kingdom.
  • Pediatric Ophthalmology Unit, Meyer Children's Hospital, Florence, Italy.
  • Biostatistic Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, United Kingdom.

ORCID-Profile: Ilaria Maccora

Zitieren

APA

Maccora, I., Guly, C., de Libero, C., Carreras, G., Ramanan, A. V., & Simonini, G. (2026). Treatment of a large cohort of childhood chronic non‐infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapy. Arthritis & Rheumatology. https://doi.org/10.1002/art.70090

Vancouver

Maccora I, Guly C, de Libero C, Carreras G, Ramanan AV, Simonini G. Treatment of a large cohort of childhood chronic non‐infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapy. Arthritis & Rheumatology. 2026. doi:10.1002/art.70090

BibTeX
@article{Maccora2026,
  author = {Maccora, Ilaria and Guly, Catherine and de Libero, Cinzia and Carreras, Giulia and Ramanan, Athimalaipet V and Simonini, Gabriele},
  title = {Treatment of a large cohort of childhood chronic non‐infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapy},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70090}
}
Kostenlos starten →